Skip to main content

Table 1 Demographic, clinical, and pathological characteristics of patients

From: UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression

 

All patients

(N = 190)

Age, M (Q1-Q3)

63 (58-67)

Race, n(%)

 Non-black

99 (52)

 Black

91 (48)

Year of Surgery, M (Q1-Q3)

2001 (1997-2002)

PSA (ng/mL), M (Q1-Q3)

7.4 (5.1-11.1)

Pathological Gleason, n(%):

 2 – 6

39 (20)

 (3 + 4)

100 (53)

 (4 + 3) – 10

51 (27)

Positive Margins, n(%)

115 (61)

Seminal Vesicle Invasion, n(%)

28 (15)

Extracapsular Extension, n(%)

51 (27)

Positive Lymph Nodes, n(%)

1 (<1)

Average % Cells Positive for UGT2B15, M(Q1-Q3)

39 (24-61)

Average % Cells Positive for UGT2B17, M(Q1-Q3)

74 (59-86)

Average % Cells Positive for UGT2B28, M(Q1-Q3)

77 (60-91)

UGT2B15 H-score, M(Q1-Q3)

40 (24-63)

UGT2B17 H-score, M(Q1-Q3)

76 (59-92)

UGT2B28 H-score, M(Q1-Q3)

86 (64-107)

PSA Follow-up (months), M(Q1-Q3)

118 (85-144)

  1. SD standard deviation, M median; Q1 25th percentile; Q3 75th percentile; BMI body mass index, PSA prostate specific antigen